天天精品资源在线观看,亚洲精品在线影院,女性私人爽爽影院免费观看国产,亚洲中文字幕aⅴ天堂自拍

  • Pharmaceutical Medicine
    • 數(shù)據(jù)庫收錄SCIE
    • 年發(fā)文量44

    Pharmaceutical Medicine

    期刊中文名:制藥醫(yī)學(xué)ISSN:1178-2595E-ISSN:1179-1993

    該雜志國際簡稱:PHARM MED,是由出版商Springer Nature出版的一本致力于發(fā)布--研究新成果的的專業(yè)學(xué)術(shù)期刊。主要發(fā)表刊登有創(chuàng)見的學(xué)術(shù)論文文章、行業(yè)最新科研成果,扼要報道階段性研究成果和重要研究工作的最新進展,選載對學(xué)科發(fā)展起指導(dǎo)作用的綜述與專論,促進學(xué)術(shù)發(fā)展,為廣大讀者服務(wù)。該刊是一本國際優(yōu)秀雜志,在國際上有很高的學(xué)術(shù)影響力。

    基本信息:
    期刊簡稱:PHARM MED
    是否OA:未開放
    是否預(yù)警:
    Gold OA文章占比:41.41%
    出版信息:
    出版周期:6 issues per year
    出版語言:English
    出版商:Springer Nature
    評價信息:
    JCR分區(qū):Q2
    影響因子:3.1
    CiteScore:5.1
    雜志介紹 JCR分區(qū) CiteScore 投稿經(jīng)驗

    雜志介紹

    Pharmaceutical Medicine雜志介紹

    《Pharmaceutical Medicine》是一本以English為主的未開放獲取國際優(yōu)秀期刊,中文名稱制藥醫(yī)學(xué),本刊主要出版、報道領(lǐng)域的研究動態(tài)以及在該領(lǐng)域取得的各方面的經(jīng)驗和科研成果,介紹該領(lǐng)域有關(guān)本專業(yè)的最新進展,探討行業(yè)發(fā)展的思路和方法,以促進學(xué)術(shù)信息交流,提高行業(yè)發(fā)展。該刊已被國際權(quán)威數(shù)據(jù)庫SCIE收錄,為該領(lǐng)域相關(guān)學(xué)科的發(fā)展起到了良好的推動作用,也得到了本專業(yè)人員的廣泛認可。該刊最新影響因子為3.1,最新CiteScore 指數(shù)為5.1。

    英文介紹

    Pharmaceutical Medicine雜志英文介紹

    pharmaceutical Medicine Is A Specialist Discipline Concerned With Medical Aspects Of The Discovery, Development, Evaluation, Registration, Regulation, Monitoring, Marketing, Distribution And Pricing Of Medicines, drug-device And drug-diagnostic Combinations. The Journal Disseminates Information To Support The Community Of Professionals Working In These Highly Inter-related Functions. Key Areas Include Translational Medicine, Clinical Trial Design, Pharmacovigilance, Clinical Toxicology, drug Regulation, Clinical Pharmacology, Biostatistics And Pharmacoeconomics. The Journal Includes:overviews Of Contentious Or Emerging Issues.comprehensive Narrative Reviews That Provide An Authoritative Source Of Information On Topical Issues.systematic Reviews That Collate Empirical Evidence To Answer A Specific Research Question, Using Explicit, Systematic Methods As Outlined By Prisma Statement.original Research Articles Reporting The Results Of Well-designed Studies With A Strong Link To Wider Areas Of Clinical Research.additional Digital Features (including Animated Abstracts, Video Abstracts, Slide Decks, Audio Slides, Instructional Videos, Infographics, Podcasts And Animations) Can Be Published With Articles; These Are Designed To Increase The Visibility, Readership And Educational Value Of The Journal’s Content. In Addition, Articles Published In Pharmaceutical Medicine May Be Accompanied By Plain Language Summaries To Assist Readers Who Have Some Knowledge Of, But Not In-depth Expertise In, The Area To Understand Important Medical Advances.all Manuscripts Are Subject To Peer Review By International Experts. Letters To The Editor Are Welcomed And Will Be Considered For Publication.

    JCR分區(qū)(2023-2024年最新版)

    Pharmaceutical Medicine雜志 JCR分區(qū)信息

    按JIF指標(biāo)學(xué)科分區(qū)
    學(xué)科:PHARMACOLOGY & PHARMACY
    收錄子集:ESCI
    分區(qū):Q2
    排名:126 / 354
    百分位:

    64.5%

    按JCI指標(biāo)學(xué)科分區(qū)
    學(xué)科:PHARMACOLOGY & PHARMACY
    收錄子集:ESCI
    分區(qū):Q2
    排名:136 / 354
    百分位:

    61.72%

    JCR分區(qū):JCR分區(qū)來自科睿唯安公司,JCR是一個獨特的多學(xué)科期刊評價工具,為唯一提供基于引文數(shù)據(jù)的統(tǒng)計信息的期刊評價資源。每年發(fā)布的JCR分區(qū),設(shè)置了254個具體學(xué)科。JCR分區(qū)根據(jù)每個學(xué)科分類按照期刊當(dāng)年的影響因子高低將期刊平均分為4個區(qū),分別為Q1、Q2、Q3和Q4,各占25%。JCR分區(qū)中期刊的數(shù)量是均勻分為四個部分的。

    CiteScore 評價數(shù)據(jù)(2024年最新版)

    Pharmaceutical Medicine雜志CiteScore 評價數(shù)據(jù)

    • CiteScore 值:5.1
    • SJR:0.732
    • SNIP:0.926
    學(xué)科類別 分區(qū) 排名 百分位
    大類:Medicine 小類:Pharmacology (medical) Q2 100 / 272

    63%

    大類:Medicine 小類:Pharmacology Q2 156 / 313

    50%

    歷年影響因子和期刊自引率

    投稿經(jīng)驗

    Pharmaceutical Medicine雜志投稿經(jīng)驗

    該雜志是一本國際優(yōu)秀雜志,在國際上有較高的學(xué)術(shù)影響力,行業(yè)關(guān)注度很高,已被國際權(quán)威數(shù)據(jù)庫SCIE收錄,該雜志在綜合專業(yè)領(lǐng)域?qū)I(yè)度認可很高,對稿件內(nèi)容的創(chuàng)新性和學(xué)術(shù)性要求很高,作為一本國際優(yōu)秀雜志,一般投稿過審時間都較長,投稿過審時間平均 ,如果想投稿該刊要做好時間安排。版面費不祥。該雜志近兩年未被列入預(yù)警名單,建議您投稿。如您想了解更多投稿政策及投稿方案,請咨詢客服。

    免責(zé)聲明

    若用戶需要出版服務(wù),請聯(lián)系出版商。